Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model

Table 3 Univariate and multivariate analyses of prognostic factors for progression-free survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Sex (female vs male)	1.08 (0.67-1.74)	0.757
Age (< 60 vs ≥ 60), years	0.89 (0.56-1.42)	0.629
BMI (≥ 25 vs < 25), kg/m2	1.28 (0.73-2.26)	0.386
CEA (< 3 vs ≥ 3), ng/mL	1.45 (0.92-2.29)	0.107
CA199 (< 37 vs ≥ 37), U/mL	1.29 (0.81-2.06)	0.278
ECOG (0 vs 1)	1.62 (0.97-2.68)	0.063
Staging (3 vs 4)	4.68 (2.71-8.11)	< 0.001	4.61 (2.53-8.41)	< 0.001
Differentiation (low vs medium-high)	0.14 (0.03-0.56)	0.006	0.20 (0.05-0.83)	0.027
Site (stomach vs gastric and esophageal binding)	1.36 (0.81-2.28)	0.252
Liver metastasis (no vs yes)	1.61 (0.98-2.66)	0.060
Peritoneal metastasis (no vs yes)	1.51 (0.96-2.37)	0.076
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	0.17 (0.10-0.29)	< 0.001	0.37 (0.22-0.64)	< 0.001
MMR status (dMMR vs pMMR)	0.12 (0.04-0.37)	< 0.001	0.28 (0.08-0.94)	0.040
EBV status (infect vs no-infect)	0.57 (0.21-1.56)	0.274
CALLY index	0.88 (0.82-0.94)	< 0.01	0.91 (0.85-0.99)	0.020
NLR	1.14 (1.08-1.22)	< 0.001	1.13 (1.05-1.22)	< 0.001
SII	1.07 (1.00-1.14)	0.052

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; ECOG: Eastern Cooperative Oncology Group; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; EBV: Epstein-Barr virus; CALLY: C-reactive protein-albumin-lymphocyte; NLR: Neutrophil-to-lymphocyte ratio; SII: Systemic immune inflammation.